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We evaluated the diagnostic quality of image-guided multisampling core needle biopsy (CNB) in patients investigated for suspected
lymphoma in a primary care hospital. A total of 112 patients were consecutively assessed during a 3-year period. There were 80
lymphoid site biopsies and 32 non-lymphoid site biopsies. Eight to nine cores were obtained from different parts of the biopsy site.
Two cores were systematically frozen, allowing for further morphological, immunochemistry and molecular studies. The diagnostic
yield of CNB for malignancy was 100%. Only 47% (41/87) of patients with initial suspicion of lymphoma were finally diagnosed with
Lymphoma. The diagnostic yield of CNB for lymphoma typing was 98% (62/63), according to the WHO classification. The diagnostic
yield of CNB for complete lymphoma subtyping/grading was 86% (54/63). The diagnostic yield of CNB for a definite diagnosis of
benignity was only 47% (8/17). In a primary care setting, multisampling CNB is a minimally invasive, and very accurate procedure for
confirming malignancy in patients with suspected lymphoma, presenting with superficial/deep-seated, lymphoid/non-lymphoid site
targets. With a very high diagnostic yield for lymphoma typing and a high diagnostic yield for complete lymphoma subtyping/grading a
therapeutic decision can be taken in most patients.
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There is a clear trend in oncological diagnostic work-up, which
was initiated in breast imaging, towards performing multisampling
core needle biopsy (CNB) of suspected lesions to obtain samples of
good quality and quantity. However, the excisional biopsy of
enlarged lymph nodes is still advocated as the gold standard in the
diagnostic evaluation of lymphoma (Dreyling, 2008; Engert and
Dreyling, 2008; Tilly and Dreyling, 2008). Nonetheless, in several
centres, percutaneous image-guided CNB, which is a minimally
invasive procedure, is used as an alternative to excisional biopsy
for diagnosing lymphomas (de Kerviler et al, 2000; Demharter
et al, 2001; Screaton et al, 2002; Balestreri et al, 2005; Li et al, 2005;
Sklair-Levy et al, 2005; Lachar et al, 2007; de Kerviler et al, 2007; de
Larrinoa et al, 2007). This is particularly true if suspected nodes or
masses are deep seated or if the clinical condition of patients is
severely impaired. This procedure needs further validation,
particularly relating to its use in a primary care hospital, where
a large differential diagnosis for peripheral/deep-seated lymph
node(s) or masse(s) exists. In our institution, image-guided large-
cutting coaxial multisampling CNB is the routine diagnostic
approach of all suspected peripheral/deep-seated lymph nodes or
tissular masses. We retrospectively evaluated the diagnostic quality
of this procedure during a 3-year period, in a series of consecutive
patients investigated for suspected lymphoma.
MATERIALS AND METHODS
Patients
All patients of the Internal Medicine Department with a
presumptive diagnosis of lymphoma on the basis of clinical
presentation and imaging findings were referred to the Imaging
Department for image-guided CNB. Before the CNB procedure, a
review of all imaging and medical records was carried out with the
medical staff to choose the most appropriate biopsy target. No
patient with suspected lymphoma had fine-needle aspiration
cytology before CNB. Informed consent for the procedure was
obtained from each patient.
Clinical staging of presumptive LPD was based on distri-
bution of disease according to the Ann Arbor clinical staging
classification.
We retrospectively evaluated CNB procedures in all
patients (47 women, 65 men; age range, 20–91 years; mean age,
58 years) assessed by image-guided CNB for suspected LPD,
during a 3-year period. No patient was excluded because of
insufficient material on CNB. CNB procedure was evaluated in
112 patients.
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sEighty-seven patients had an initial presentation of suspected
lymphoma. Of these, 11 had a previous malignancy (urothelial, 4;
breast, 1; colic, 1; pulmonary, 1; melanoma, 2; ovary, 1; uterus, 1)
but clinical presentation, localisation and delay of appearance of
suspected lesions were rather suggestive of lymphoma.
Twenty-five patients had a previous history of lymphoma.
Indication for biopsy was a suspicion of relapsed or histological
transformation of the disease.
Biopsy procedures were performed on an outpatient basis
(70%), unless the patient status necessitated hospitalisation (30%).
Biopsy sites and image-guided biopsy procedure
All patients had image-based staging with cervico-thoraco-
abdominal-enhanced CT. When several lymphoid/non-lymphoid
site targets were available, biopsy of peripheral targets was
preferred over biopsy of deep-seated targets when both were
present. There were 80 lymphoid site biopsies (peripheral, 37; deep
seated, 43) and 32 non-lymphoid site biopsies (peripheral, 6; deep
seated, 26; Table 1). Peripheral sites were biopsied under
sonographic guidance whereas deep-seated sites were biopsied
under CT guidance.
A coagulation screen was only obtained before a deep-seated
target biopsy procedure (exclusion criteria for the biopsy were a
prothrombin time o60% or a platelet count o50000 per ml).
Premedication was generally not given. The biopsy procedure was
standardised and performed by experienced radiologists (PL or
MC).
In the case of biopsy under contrast-enhanced CT guidance,
selected images were obtained in the area of interest (1.5mm beam
collimation, 3mm reconstruction thickness, 3mm reconstruction
interval, 1.25 pitch, 0.75s rotation time, 120Kvp and 180MAs).
Patients were told to breathe in a slow, regular and shallow manner
throughout the biopsy procedure and during acquisition of
images. It is our personal experience that breathing instructions,
such as suspended inspiration or expiration, raise the difficulty of
the procedure, because they are not always reproducible. Local
anaesthesia using 5–10ml of xylocaine was carefully performed
along the chosen tract of the biopsy procedure, and then an
adjustable coaxial 17-gauge automated CNB system (Temno
Biopsy System; Allegiance Healthcare Corporation, McGaw Park,
IL, USA) was used. The system consists of a 17-gauge (1.48mm
diameter) outer cannula with an introducer stylet that is used for
positioning the outer cannula. Once its tip is on the surface of the
lesion, the stylet is taken out and an 18-gauge (1.25mm diameter)
central cutting needle biopsy is passed through the cannula for
biopsy sample. The sample length can be selected to a maximum of
24mm by turning a coaxial bolt. Eight/nine cores, considered
macroscopically adequate by the radiologist, were obtained from
different parts of the lesion by slightly modifying the orientation of
the cannula. The criterion for a macroscopically adequate core was
extraction of a sharply cut tissue core. In the case of large lesions,
biopsy of the peripheral portion of the lesion was preferred to
avoid possible biopsy of necrotic tissue in the central region. In
lymph nodes, the peripheral capsule was systematically sampled.
Duration of sample harvesting was less than 15min. Biopsy
samples were separated and immediately sent to the laboratory in
part unfixed and in part fixed (in buffered formaldehyde) for
immediate processing. A ratio of 2/3 fixed and 1/3 unfixed was
generally used (three cores were unfixed). This material was
forwarded along with a sheet that detailed the clinical history of the
patient.
Search for complications
After removal of the biopsy system, immediate postbiopsy
complications were monitored. In cases of a deep-seated target
biopsy procedure, outpatients were transferred to a holding unit
and kept under observation for 2h and were discharged if there
were no significant complications. They were encouraged to
contact their physicians if they developed symptoms after leaving
hospital.
Histopathological examination
A haemato-histopathologist (TMK) reviewed all specimens. The
priority with fresh (unfixed) samples was given to storage in a
tissue bank to allow subsequent molecular analysis if judged
necessary (two samples). Remaining unfixed material was
dissociated and analysed by flow cytometry.
Fixed samples were embedded in paraffin and stained with
haematoxylin and eosin and Giemsa stains. The histological
appearance dictated the choice of antibodies for immunohisto-
chemical stains. Lymphoid infiltrates were characterised using an
appropriate selection of antibodies (from CD45, CD3, CD4,
CD5, CD8, CD10, CD15, CD 20, CD21, CD23, CD30, CD43,
CD79a, BCL-1, BCL-2, BCL-6, IRF4 and MIB1). If necessary,
sections were cut for analysis by fluorescence in situ hybridisation
using selected probes (from IGH, CCND1, BCL2, MALT, MYC; 4
cases). Fresh frozen material was available to allow T- or B-cell
clonality studies and the translocations [1] (14;18) and (11;14) to
be characterised using primer sets defined by the BIOMED
consortium (29 cases), and also for further molecular analysis if
necessary (identification of microorganisms such as mycobacteria,
EBV, HHV-8, etc.; 7 cases). Flow cytometry was performed in
further seven cases.
The recently established revised European–American classifica-
tion of lymphoid neoplasmas and the subsequently adopted and
updated World Health Organisation (WHO) classification of
tumours of haematopoietic and lymphoid tissues were used to
classify lymphomas.
Metastatic tumours were identified by standard histological
analysis and immunochemistry if necessary. Histopathology
reports were reviewed for evaluation of diagnostic yield of CNB.
Table 1 Distribution and diameter of biopsied lesions in 112 patients
with suspected lymphoma
Initial presentation
lymphoma (n¼87)
Relapsed/
transformed
lymphoma (n¼25)
Lymphoid sites
Retroperitoneum 23 (20–130mm; 40mm) 5 (15–100mm; 48mm)
Neck/cervical 13 (15–80mm; 33mm) —
Mediastinum 11 (30–90mm; 55mm) —
Axilla 8 (10–90mm; 33mm) 4 (20–40mm; 29mm)
Groin 5 (20–60mm; 42mm) 2 (20mm)
Supraclavicular 4 (10–60mm; 29mm) 1 (30mm)
Spleen 3 (90–120mm; 103mm) —
Porta hepatic — 1 (20mm)
Non-lymphoid sites
Chest wall 5 (35–100mm; 63mm) 2 (30, 35mm)
Abdomen 4 (50–100mm; 72mm) 2 (50, 60mm)
Muscle 3 (30–60mm; 45mm) 2 (35, 50mm)
Lung 2 (35, 40mm) 2 (25, 30mm)
Adrenal 1 (50, 80mm) —
Spine 2 (30, 45mm) —
Liver 1 (40mm) 3 (10–20mm; 15mm)
Bone 1 (100mm) —
Kidney 1 (30mm) 1 (35mm)
Numbers without parentheses correspond to number of patients. Numbers in
parentheses correspond to lesion diameters, or diameter ranges with mean
diameters. Lesion size is defined by largest axis diameter.
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To estimate the validity of CNB in the context of suspected LPD
seen in a primary care institution, the following parameters were
analysed:
The diagnostic yield of CNB to establish the diagnosis of a
malignant disease (lymphoma or others) is the ratio of the number
of malignant diagnoses on CNB divided by the number of
malignant diagnoses at final diagnostic work-up.
The diagnostic yield of CNB to establish the diagnosis of a
benign process is the ratio of the number of definite benign
diagnoses made by CNB by the number of benign diagnoses at
final diagnostic work-up (i.e., subsequent surgical biopsy,
laboratory tests or clinical follow-up during a 1-year period).
The diagnostic yield of CNB for lymphoma typing is the ratio of
the number of cases for which a precise diagnosis of lymphoma
was made on CNB, divided by the number of the entire cohort of
lymphomas.
The diagnostic yield of CNB for lymphoma subtyping is the ratio
of the number of cases for which the subtype (e.g., germinal centre
vs activated type for DLBCL) or the grading (e.g., for follicular
lymphomas (FLs)) was made on CNB, divided by the number of
the entire cohort of lymphomas.
For cases of incomplete lymphoma typing/subtyping/grading,
retrieved data were used to assess whether subsequent surgical
biopsy was proposed or CNB results were considered as sufficient
for adapted therapeutic decision.
RESULTS
Of the 112 patients addressed for CNB, 87 had an initial
presentation of suspected lymphoma and 25 had suspected
relapsed/transformed lymphoma.
The tolerance of the procedure was excellent. No patient had
severe pain requiring the interruption of the biopsy. On clinical or
imaging follow-up, only minor complications were noted, one
small pneumothorax, a 3-cm diameter cervical haematoma and a
4cm diameter adrenal haematoma. They all resolved sponta-
neously.
Histopathological analysis of CNB samples showed malignant
diagnoses in 95 patients (63 lymphomas and 32 non-lymphomas),
benign diagnoses in 8 patients and non-malignant diagnoses
without definitively excluding lymphoma in 9 patients (Tables 2).
The diagnostic yield of CNB for malignancy (number of malignant
diagnoses on CNB/number of malignant diagnoses at final
diagnostic work-up) was 100%, indicating that no case of
malignancy was missed by a careful CNB examination. It is
noteworthy that only 45% (41/87) of patients with initial suspicion
of lymphoma were finally diagnosed with lymphoma, with CNB
revealing 32 cases of other cancers (metastatic or primary) and 14
cases of non-malignant processes. These data strengthen the
potential of the CNB approach in the context of a primary care
hospital where a large diversity of diagnoses is expected. It is also
noteworthy that 10 out of 25 patients with suspected relapsed/
transformed lymphoma had a CNB diagnosis different from initial
lymphoma diagnosis (Table 3).
In contrast, the diagnostic yield of CNB for a definite diagnosis
of benignity was only 47% (8/17). This underlines the difficulty of
obtaining a precise diagnosis of a benign disorder with CNB
samples. However, except for one patient who was lost to follow-
up, the absence of lymphoma was confirmed in all other eight
cases. In two cases of necrotising granulomatous inflammation, the
diagnosis of tuberculosis was established by cultures; two patients
with peripheral lymph nodes spontaneously recovered within a few
months and four patients underwent surgical exploration to excise
entire lymph nodes, which confirmed the benign nature of
the disease (Table 4). The most important endpoint of this study
was to define whether CNB is an appropriate strategy for the
diagnosis of lymphoma arising in a patient population from a
primary care institution. The diagnostic yield of CNB for
lymphoma typing was 98% (62/63; Table 2). For one patient only,
the material provided by CNB was insufficient to make the
differential diagnosis between Hodgkin’s lymphoma and anaplastic
large cell lymphoma. He declined surgical exploration and was lost
to follow-up. For all other patients, a precise diagnosis according
to the WHO classification was established.
A detailed description of nodal architecture, cell characteristics
and interstitial fibrosis may influence the treatment choice or
Table 2 Distribution of CNB results in 112 patients with suspected
lymphoma
Lymphoma with complete subtyping/grading (54)
DLBCL activated type 13
DLBCL germinal centre type 8
MCL 3
Anaplastic large cell lymphoma 3
Nodular sclerosis classical HL 4
Nodular lymphocyte predominant HL 2
Mixed cellularity classical HL 2
Lymphocyte-rich classical HL 1
FL grade 3 3
FL grade 2 1
FL grade 1 1
Monomorphic PTLD (DLBCL type) 1
Precursor T-lymphoblastic lymphoma 1
Angioimmunoblastic T-cell lymphoma 1
DLBCL, follicular lymphoma in transformation 1
Castelman disease 1
High-grade lymphoma, blastoid transformation 1
Lymphoplasmocytic lymphoma 1
Burkitt lymphoma 1
Precursor B-lymphoblastic lymphoma 1
CLL in transformation (Richter syndrome) 1
CLL 1
Multiple myeloma 2
Lymphoma, incomplete subtyping/grading (8)
Classical HL 4
DLCBL 2
FL grading not specified 1
B-cell lymphoma 1
Lymphoma, incomplete typing (1)
HL or anaplastic large cell lymphoma 1
Non-lymphoma malignant diagnoses (32)
Epithelial tumours 23
Non-e ´pithe ´lial tumours 9
Benign diagnoses (8)
Pyogenic acute inflammation with fungus 1
Granulomatous lymphadenitis (BAAR+) 3
Necrotising granulomatous inflammation (PCR :DNA of MT) 2
Non-specified periportal inflammation 1
BOOP 1
Non-malignant diagnoses. Lymphoma could not be definitively ruled out on CNB results
(9)
Mix lymphocytic infiltrate 1
Necrotising granulomatous inflammation 2
Benign fibroadipose tissue 1
Non-necrotising non-granulomatous reactive lymphadenitis 1
Acute and chronic inflammation 1
Reactive lymphoid tissue without tumour 1
Lymphoid tissue with follicular hyperplasia 2
DLBC¼diffuse large B-cell lymphoma; MCL¼mantle cell lymphoma; HL¼Hodg-
kin’s lymphoma; FL¼follicular lymphoma; PTLD¼post-transplantation lymphopro-
liferative disease; CLL¼chronic lymphatic leukaemia; BAAR¼acid-alcohol resistant
bacillus; PCR¼polymerase chain reaction; DNA¼deoxyribonucleic acid; MT¼
Mycobacterium tuberculosis; BOOP¼bronchiolitis obliterans organised pneumonia.
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CNB for complete lymphoma subtyping/grading was 86% (54/63).
Among the eight cases with incomplete lymphoma subtyping/
grading, there were four classical Hodgkin’s lymphoma for which
the histological subtype could not be determined. However, the
treatment decision for early or advanced stages of Hodgkin’s
lymphoma relies on well-defined prognostic factors that do not
include the subtype. There were two DLBCL, for whom there was
not enough material to discriminate between germinal centres and
activated subtypes, but it has not yet been agreed that treatment
intensity should consider these parameters. There were two
patients with a history of low-grade lymphoma. The first case
was a patient relapsing five years after the diagnosis of grade 1 FL.
The biopsy of a retroperitoneal lymph node confirmed the
diagnosis of FL, but a precise grading was not possible. However,
the patient was symptomatic with important tumour masses and
his treatment was dictated by these clinical parameters. The last
case was a patient with a known low-grade lymphoma, which was
unclassifiable based on in-depth analysis of an entire lymph node.
At the time of relapse, 3 years later, the same pathological
characteristics were found in CNB samples, including the same B-
cell receptor rearrangement. Due to the indolent clinical course, a
wait and see attitude was preferred.
We wondered whether technical CNB difficulties related to the
size or the location of lymph nodes/masses could explain
incomplete lymphoma typing/subtyping/grading. For the nine
cases of incomplete lymphoma typing/subtyping/grading (one case
of incomplete lymphoma typing and eight cases of incomplete
lymphoma subtyping/grading), diameters of biopsy targets were
random, ranging from 15 to 90mm (mean, 37.8mm). In contrast,
biopsy sites were deep seated in seven out of nine cases suggesting
that the location of the target, rather than the size, could constrain
an optimal sampling technique.
DISCUSSION
A precise histological diagnosis using current classification
systems is a critical step for guiding appropriate treatment choices
in lymphoma. This requires sufficient material to allow recognition
of complex architectural patterns, realisation of numerous
immunophenotyping procedures and, more and more frequently,
complex molecular analyses that are often the final proof for a
suspected diagnosis. Consequently, entire lymph node resection is
still considered as the method of choice, mainly for peripheral
lymph nodes. However, deep-seated lymph nodes or masses
remain a challenge. In this situation, surgery may be difficult to
achieve within a few days (a short period which is often necessary
in the context of aggressive lymphoma), is expensive and may
induce several postoperative complications that further delay the
initiation of curative chemotherapy.
Needle aspiration cytology (NAC) has been seen as a valuable
alternative diagnostic procedure. However, it requires specific
cytopathological expertise (not available in all centres, at least in
Europe), and has important limitations (e.g., there is no
information about nodal architecture, less material for immuno-
histochemical and molecular analysis,y). Such intrinsic draw-
backs are more and more critical with the current view of
lymphoma diagnosis that requires the coordinated interpretation
of structural, phenotypic and genotypic characteristics. Some
authors reported a high diagnostic rate was with NAC (Gold-
schmidt et al, 2003; Agid et al, 2005), and others reported that NAC
misguided lymphoma diagnosis (Hehn et al, 2004). Nonetheless, it
is clear that cytological analysis can provide a rapid diagnosis in
specific clinical situations such as (1) metastatic carcinomas or (2)
aggressive lymphoma, where a rapid diagnosis allows therapy to be
initiated without the delay that results from fixation and
processing of biopsy material (touch prints of biopsies can also
be used for this purpose).
Image-guided CNB is a minimally invasive procedure offering a
distinct advantage over FNAC in that it obtains intact tissue. A
strategy for obtaining a large amount of tissue is the use of an
automated large-cutting biopsy gun with a coaxial technique. The
main advantage of the coaxial technique is its ability to sample
several core specimens with a single biopsy tract. A cannula is first
inserted through the skin and towards the lesion. The cannula
remains in position during the sampling procedure, thus decreas-
ing the potential risk of postprocedure complications and tumour
cell spreading. By slightly modifying the orientation of the cannula,
multiple samples can be obtained in different representative
portions of the lesion, providing valuable information (while
partial) on nodal architecture in most cases. Thus, image-guided
Table 3 CNB results in 10 patients with suspected relapsed/transformed
lymphoma for whom the CNB diagnosis was different from initial diagnosis
Initial diagnoses Diagnoses at CNB
MCL High-grade lymphoma, blastoid
transformation
Grade 3 FL DLBCL
Lymphoplasmocytic lymphoma Grade 1 FL
Lymphocyte-rich classical HL Nodular lymphocyte predominant HL
DLBCL germinal centre
subtype
CLL in transformation (Richter syndrome)
Nodular sclerosis classical HL Grade 2 FL
HL Nodular lymphocyte predominant HL
BCL (HIV+) Non-specified periportal inflammation
Nodular sclerosis classical HL BOOP
Nodular sclerosis classical HL Reactive lymphoid tissue with follicular
hyperplasia
MCL¼mantle cell lymphoma; FL¼Follicular lymphoma; DLBC¼diffuse large B-cell
lymphoma; HL¼Hodgkin’s lymphoma; CLL¼chronic lymphatic leukaemia; BCL¼
B-cell lymphoma; BOOP¼bronchiolitis obliterans organised pneumonia.
Table 4 Diagnostic work-up of nine patients with non-malignant
diagnoses at CNB for whom lymphoma could not be definitively ruled
out by CNB results
CNB results
Final diagnostical
procedure Final diagnosis
Mix lymphocytic
infiltrate
Patient lost of
follow-up
Histological result of CNB
could not be confirmed
Necrotising granulomatous
inflammation
Cultures positive
for MT
Tuberculosis
Necrotising
granulomatous
inflammation
Bronchoscopy
Cultures positive
for MT
Tuberculosis
Benign fibroadipose
tissue
Spontaneous resolved
process on follow-up
Benign axillary lymph node
Non-necrot.. non-granulo.
react. lymphadenitis
Resolved process on
clinical follow-up
Benign cervical lymph node
Acute and chronic
inflammation
Subsequent surgical
biopsy of the identical
lymph node
Acute and necrotising
lymph node inflammation
Reactive lymphoid tissue
without tumour
Subsequent surgical
biopsy of the identical
lymph node
Fibrosis and chronic lymph
node inflammation
Lymphoid tissue with
follicular hyperplasia
Subsequent surgical
biopsy of the identical
lymph node
Reactive lymph node
follicular hyperplasia
Reactive lymphoid tissue
with follicular hyperplasia
Subsequent surgical
biopsy of the identical
lymph node
Reactive lymph node
follicular hyperplasia
MT¼Mycobacterium tuberculosis.
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the diagnosis of deep-seated lymphomas (de Kerviler et al, 2000;
Demharter et al, 2001; Balestreri et al, 2005; Li et al, 2005; Sklair-
Levy et al, 2005; Lachar et al, 2007; de Larrinoa et al, 2007), and in
some institutions for suspect peripheral lymph nodes (Screaton
et al, 2002; de Kerviler et al, 2007). Although variable endpoints
were analysed in those studies with highly diverse designs, CNB
appears to be a valuable approach with sensitivity for diagnosing
lymphoma at 87–89% (Demharter et al, 2001; Balestreri et al,
2005), overall diagnostic yield at 84% (Sklair-Levy et al, 2005),
unequivocal diagnosis of lymphoma at 91% (Lachar et al, 2007),
overall diagnostic accuracy for lymphoma typing at 88% (de
Larrinoa et al, 2007), sufficient information such that a therapeutic
decision could be made at 96% (de Kerviler et al, 2007) and
diagnosis of lymphoma with subtyping ranging from 76 to 85% (de
Kerviler et al, 2000; Li et al, 2005).
However, the validity of CNB for lymphoma diagnosis is still
controversial, and entire lymph node removal is often proposed as
the best procedure (Dreyling, 2008; Engert and Dreyling, 2008;
Tilly and Dreyling, 2008). Moreover, most of the studies (de
Kerviler et al, 2000; Demharter et al, 2001; Screaton et al, 2002;
Balestreri et al, 2005; Li et al, 2005; Sklair-Levy et al, 2005; de
Kerviler et al, 2007; de Larrinoa et al, 2007; Lachar et al, 2007)
include patients with a high probability of lymphoma diagnosis
assessed in reference centres for lymphoproliferative diseases. This
study was designed to determine whether CNB can also be
recommended in the context of a primary care hospital where a
large range of malignant and benign diagnoses can be expected. In
an attempt to optimise the accuracy of CNB in this challenging
setting, a large number of samples were collected, whereas the
mean number of samples harvested in the previous studies varied
from 1 to 4.5. Moreover, although this was apparently achieved in
one previous series only (de Kerviler et al, 2007), fresh tissue was
used for flow cytometry analysis and two cores of tissue were
systematically frozen, allowing for further morphological, immu-
nochemistry and molecular studies. Those additional samples were
useful to establish a precise diagnosis in 40% of cases (data not
shown).
Regarding the large differential diagnosis expected in this
patient population, several end-points were considered in this
study. The diagnostic yields of multisampling CNB for malignancy,
lymphoma typing and complete lymphoma subtyping/grading
were 100, 98 and 86%, respectively. This indicates that no case of
malignancy was missed, that the diagnosis of lymphoma was
established in all but one case, and a precise subtyping/grading
was possible in 55/63 cases. It is important to note that the lack of
precise subtyping/grading in a minority of cases did not preclude a
therapeutic decision to be made for 62/63 patients (98%) with
lymphoma. These rates not only compare favourably with those
obtained in more homogeneous patient populations (de Kerviler
et al, 2000, 2007; Demharter et al, 2001; Screaton et al, 2002;
Balestreri et al, 2005; Li et al, 2005; Sklair-Levy et al, 2005; de
Larrinoa et al, 2007; Lachar et al, 2007) but also with results
usually obtained by complete lymph node analysis. On the other
hand, the diagnostic yield of CNB for diagnosis of benignity was
only 53%, confirming that a definitive diagnosis for a benign
disorder is a difficult task. However, careful follow-up and/or
surgical exploration allowed lymphoma to be excluded in all
uncertain cases (n¼8). This further demonstrates that CNB,
performed in patients with suspected LPD in the context of a large
differential diagnosis, permitted not only a precise diagnosis of
lymphoma to be made but also lymphomas to be distinguished
from other malignant diseases and benign processes.
CNB may have some intrinsic weakness for lymphomas with
complex architecture, few or polymorphic tumour cells or a strong
reactive cellular process as exemplified by the difficulty in defining
the subtype of Hodgkin’s lymphoma and in grading all cases of FL.
The diagnostic value of CNB in certain other situations (e.g.,
T-cell-enriched B-cell or T-cell lymphoma) could not be estab-
lished by this study, because of the non-selective accrual of
patients in our institution and, as a result, the low number of
such lymphoma entities. However, T-cell lymphomas tend to be
rare, and even in reference centres, at least in Europe and
North America, usually constitute less than 5% of lymphomas
(de kerviler et al, 2007).
Such results also highlight the importance of a coordinated
approach between radiologists, pathologists and oncologists/
haematologists to optimise the diagnosis of suspected lymphomas.
Moreover, such accuracy with CNB requires review all specimens
by a haemato-histopathologist.
CONCLUSION
In a primary care setting, multisampling large-cutting CNB is a
very accurate procedure for confirming malignancy in patients
with suspected lymphoma. CNB should be the first procedure
proposed to those patients whose suspect lymph nodes or masses
are deep seated or whose clinical condition is severely impaired
and for those patients who reject a lymph node biopsy. CNB can
also be appropriate for patients with peripheral lymph nodes/
tumour masses because it is a readily available, few-invasive and
safe procedure, that has a very high diagnostic yield for lymphoma
typing and a high diagnostic yield for complete lymphoma
subtyping/grading. This allows a therapeutic decision to be taken
in most patients (98% in this series), avoiding expensive, time-
consuming and chemotherapy-delaying surgery.
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